We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 906

The State AG Report Weekly Update December 14, 2017
  • Cozen O'Connor
  • USA
  • December 14 2017

Republican state Representative Todd Atwater has declared his candidacy for South Carolina AG in 201


FDA Issues Warning to Four Companies Marketing Cannabidiol Containing Products as Anti-Cancer Treatment
  • FisherBroyles LLP
  • USA
  • November 6 2017

On November 1, 2017, the U.S. Food and Drug Administration issued warning letters to four companies that were illegally marketing and selling products


Inside the Courts - An Update From Skadden Securities Litigators
  • Skadden Arps Slate Meagher & Flom LLP
  • USA
  • November 5 2017

Judge Patti B. Saris denied the Bank of New York Mellon’s (BNY Mellon) motion to strike putative class representative Ashby Henderson. BNY Mellon


Insys Therapeutics Runs Afoul of Attorneys General in Two States
  • FisherBroyles LLP
  • USA
  • October 10 2017

Arizona-based pharmaceutical company Insys Therapeutics Inc. (Insys) has found itself under investigation in both Massachusetts and New Jersey over


Inside the Courts - An Update From Skadden Securities Litigators
  • Skadden Arps Slate Meagher & Flom LLP
  • USA
  • September 27 2017

The U.S. Supreme Court resolved a circuit split by deciding that the three-year limit for filing lawsuits under Section 13 of the Securities Act is a


Global Privacy & Cybersecurity Update Vol. 15
  • Jones Day
  • USA, European Union, Global
  • September 13 2017

On June 19, the Federal Trade Commission ("FTC") submitted comments to a working group organized by the Department of Commerce's National


First Circuit Affirms Dismissal Of Putative Securities Fraud Class Action, Finding Defendants’ Statements Concerning The Potential NDA For A Drug Candidate Came “Replete with Caveats”
  • Shearman & Sterling LLP
  • USA
  • August 29 2017

On August 22, 2017, the United States Court of Appeals for the First Circuit affirmed an order from the District of Massachusetts, dismissing a


First Circuit Affirms Dismissal of Biogen Investors’ Claims, Finding a Lack of “Connecting Detail,” in In re Biogen Inc. Securities Litigation, 857 F.3d 34
  • Lane Powell PC
  • USA
  • June 21 2017

In this putative class action, investors alleged that Biogen executives misled the public about the impact on sales of the company's multiple


Ohio Attorney General Sues Pharmaceutical Companies Over Opioid Marketing - Yet Another Sign of Government Focus on Recovering Financial Cost of Opioid Epidemic
  • Pietragallo Gordon Alfano Bosick & Raspanti LLP
  • USA
  • June 9 2017

Last week, Ohio Attorney General Mike DeWine filed a lawsuit against multiple pharmaceutical companies, including Purdue, Teva, Johnson & Johnson


FDA Issues Three Key Documents Relating to Medical Product Manufacturer Communications
  • Ropes & Gray LLP
  • USA
  • January 31 2017

On January 18, 2017, the Food and Drug Administration (“FDA”) released three key documents outlining the agency’s current thinking regarding drug and